IDA+BUCY vs BUCY Conditioning Regimen for Intermediate-risk AML Undergoing Auto-HSCT
Status:
Completed
Trial end date:
2020-02-28
Target enrollment:
Participant gender:
Summary
Autologous hematopoietic stem cell transplantation (Auto-HSCT) is an effective alternative to
allogeneic HSCT for intermediate-risk acute myeloid leukemia (AML) without HLA-matched
donors. At present, the best conditioning regimen for AML undergoing auto-HSCT remains in
discussion. In this study, the safety and efficacy of IDA+BUCY and BUCY myeloablative
conditioning regimens in intermediate-risk AML undergoing auto-HSCT are evaluated.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Nanfang Hospital of Southern Medical University
Collaborators:
Guangzhou First People's Hospital Peking University People's Hospital Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Sun Yat-sen University Third Affiliated Hospital, Sun Yat-Sen University Zhujiang Hospital